ERBB2 and breast carcinoma: It is also being investigated in combination with trastuzumab with or without fulvestrant compared to trastuzumab plus chemotherapy in previously treated patients with PIK3CA-mutated HER2-positive advanced breast cancer in phase III ALPHABET trial (NCT05063786) [123,124].